Lineage Cell Therapeutics, Inc. Common Stock

Financials

영업활동으로 인한 현금 -19.75 M-23.56 M1.06 M-28.57 M-23.09 M-18.92 M -22.11 M 투자 활동으로 인한 현금 13.04 M9.74 M-46.16 M46.45 M-2.31 M-13.46 M -17.69 M 재무활동으로 인한 현금 29.86 M36.93 M1.63 M6.42 M35.86 M26.95 M 27.47 M 잉여 현금 흐름 -19.75 M-23.56 M1.06 M-28.57 M-23.09 M-19.44 M -22.59 M

Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform, Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer.

LCTX

Financials

Lineage Cell Therapeutics, Inc. Common Stock

뉴스

Lineage Cell Therapeutics, Inc. (LCTX) Q1 2026 Earnings Call Transcript

Lineage Cell (LCTX) Reports Q1 Loss, Lags Revenue Estimates

Halozyme Therapeutics (HALO) Surpasses Q1 Earnings and Revenue Estimates

Lineage Cell Therapeutics, Inc. (LCTX) Presents at FFB Retinal Therapeutics Innovation Summit - Slideshow (NYSE:LCTX) 2026-05-07

Guardant Health (GH) Reports Q1 Loss, Beats Revenue Estimates

라인에이지 세포 치료제, 최대 6천만 달러 규모의 주식 공모 위한 투자 설명서 추가 서류 제출

Lineage Cell Therapeutics files prospectus supplement for up to $60 million share offering

H.C. 웨인라이트, Lineage Cell 주식에 ’매수’ 의견 재확인, 목표가 9달러

H.C. Wainwright reiterates Buy on Lineage Cell stock, $9 target

Lineage Cell Therapeutics, Inc. (LCTX) Q4 2025 Earnings Call Transcript

Lineage Cell Therapeutics Q1 실적, 수익 예상치를 넘어

Lineage Cell Therapeutics earnings beat by $0.05, revenue topped estimates